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Abstract
G protein-coupled receptors (GPCRs) represent one of the largest families of cell surface receptors, and are the
target of more than half of the current therapeutic drugs on the market. When activated by an agonist, the GPCR
undergoes conformational changes that facilitate its interaction with heterotrimeric G proteins, which then relay
signals to downstream intracellular effectors. Although GPCRs were thought to function as monomers, many
studies support the hypothesis that G protein coupling involves the formation of GPCR homo- and/or hetero-
complexes. These complex systems have been suggested to exhibit specific signaling cascades, pharmacological,
internalization, and recycling properties. In this review, we summarize recent advances in our understanding of the
structure, function and dynamics of GPCR complexes, as well as the findings obtained in animal models.
Introduction
G protein-coupled receptors (GPCRs) [1], also known as
seven transmembrane receptors, were initially consid-
ered to function as monomeric structural units. In the
last decade, however, there has been an increasing num-
ber of publications describing GPCR homodimers or
even higher order oligomers [2-5]. There is also evi-
dence that GPCR heterocomplexes may exist [6-8]. Two
of the main lines of research in structure and function
of GPCRs are focused on the residues and domains
responsible for GPCR complex formation, as well as the
stability and mechanisms of signaling crosstalk between
the components of these homo- and heteromers.
Another point of interest is the identification of GPCR
complexes in native tissues and their functional signifi-
cance in whole animal models. In this review, we will
summarize recent advances in our understanding of
GPCR homo- and heteromerization, as well as their
potential implication in physiological responses.
History of GPCR complexes
In the 1980s, two laboratories at the Karolinska Institute
in Stockholm and the National Institute for Medical
Research in London proposed the existence of receptor
mosaics [9,10] and a direct interaction of two receptors
with each other [11]. This hypothesis was also supported
by previous publications demonstrating negatively coop-
erative site-site interactions among the b-adrenergic
receptors [12]. Similarly, using a photoaffinity labeling
approach, Sokolovsky and collaborators proposed that
muscarinic receptors exist in interconvertible dimer and
tetramer forms [13]. They also suggested a model in
which muscarinic receptor monomers formed dimers
and tetramers joined by covalent bonds; although this
model of covalent bonding has not been confirmed.
Immunoaffinity chromatography approaches with the
b2-adrenergic receptor in mammalian lung [14], and
protocols of radiation inactivation with the a2-adrener-
gic receptor in human platelets [15] also pointed toward
the phenomenon of GPCR oligomerization. Years ear-
lier, it had been introduced the concept that antagonists
bind to the receptor with one uniform affinity whereas,
for agonists, two distinct binding sites of high and low
affinity are detected [16]. They demonstrated that the
proportion of agonist high affinity binding sites was dra-
matically decreased in the presence of guanine nucleo-
tides, and proposed the ternary complex model to
explain these findings [17]. In the 1990s, additional stu-
dies based on radioligand binding displacement curves
obtained with muscarinic [18] and dopamine D2 [19]
receptors were consistent with the idea that the tested
ligands differentially bind monomeric and dimeric
GPCRs. Potter and colleagues found that competition
curves between different agonists and antagonists with
the muscarinic receptor antagonist N-[
3H]methylscopo-
lamine ([
3H]NMS) showed the presence of equal popu-
lations of guanine nucleotide-sensitive high affinity sites
(H) and guanine nucleotide-insensitive low affinity sites
(L) in membrane preparations from rat brainstem [18].
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using irreversible ligands, and the specific blockage of
either H or L sites did not lead to changes to the
remaining binding sites. This phenomenon, which the
authors termed 50% H, was interpreted as evidence of
M2 muscarinic receptor dimerization. Seeman and colla-
borators compared the binding properties of the dopa-
mine D2 antagonists [
3H]emonapride and [
3H]spiperone
in tissue cultures and in postmortem human caudate
nucleus [19]. They found that the density of D2 recep-
tors labeled with [
3H]emonapride was twice higher than
that labeled with [
3H]spiperone. Similar findings were
obtained by positron emission tomography (PET) in
human brain when using [
11C]raclopride and [
11C]spi-
perone [20]. They proposed that [
3H]spiperone preferen-
tially binds dopamine D2 receptor dimers, whereas [
3H]
emonapride only binds to receptor monomers. These
and other observations led the authors to speculate that
GPCRs might be expressed and function as dimers or
oligomers. However, the existence of GPCR oligomeric
structures did not attract much attention, and the most
accepted model was the one proposing that a single
GPCR is sufficient to interact with a single G protein.
It was not until the findings by Wess that the concept
of GPCR complex formation gained interest among the
research field [21]. They tested the functional response
induced by chimeras of the muscarinic M3 and a2C-
adrenergic receptors. Chimeric M3/a2C receptor was
composed of the first five transmembrane domains
(including intracellular loop 3) of the muscarinic M3
receptor and the last two transmembrane domains of
the a2C-adrenergic receptor. Chimeric a2C/M3 receptor
was composed of the first five transmembrane domains
a2C-adrenergic receptor and the last two transmem-
brane domains (including intracellular loop 3) of the
muscarinic M3 receptor.
Intracellular loop 3 of the muscarinic M3 receptor was
maintained unchanged in both chimeras because this
region is responsible for the specificity of G protein cou-
pling. The signaling induced by the muscarinic receptor
agonist carbachol was abolished when either of these
two chimeras was expressed alone. However, coexpres-
sion of M3/a2C and a2C/M3 receptor chimeras rescued
the carbachol-induced signaling, which provided the first
indirect evidence for GPCR dimerization.
Two of the key findings to indicate that GPCR com-
plexes might be important in receptor signaling were
also the assembly of GABAB receptor subtypes (GABAB-
R1 and GABAB-R2) into heteromeric complexes (see
[22] for review), and the heteromerization of δ-and
-opioid receptors affecting ligand binding and receptor
signaling [23]. Since then, several laboratories have
reported the presence of GPCRs as homo- and hetero-
mers, a concept that it is now widely accepted.
Protein domains responsible for GPCR complex
formation
Much evidence indicates that class C GPCRs, including
GABAB and metabotropic glutamate (mGlu) receptors,
exist and function as constitutive dimers. Heterodimeri-
zation of GABAB receptor is mediated by parallel
coiled-coil interactions at C-termini [24-26]. Co-expres-
sion of GABAB-R1 and GABAB-R2 results in the func-
tional expression of GABAB receptor in the plasma
membrane [22]. Recently, it has also been shown that
the mGlu receptors are assembled into strict dimers
covalently bound via a disulfide bridge [27]. Closure of
both binding domains is necessary to obtain full activity
of the mGlu receptors [28]. In contrast, most of the
experiments conducted on class A GPCRs suggest that
receptor oligomers are formed through non-covalent
interactions, with the transmembrane (TM) domains as
the most likely elements involved in receptor oligomeri-
zation. We will summarize our current knowledge
regarding the TM domains that form the interface of
GPCR homo- and hetero-complexes.
Milligan and colleagues demonstrated using co-immu-
noprecipitation and fluorescence resonance energy
transfer (FRET) assays that the a1b-adrenergic receptor
forms oligomeric complexes in which symmetrical con-
tact points involving both TM1 and TM4 were detected
[29]. These experiments were performed using epitope-
tagged fragments comprising distinct TM domains.
They also found with the use of three-color FRET (3-
F R E T )t h a tt h ea1b-adrenergic receptor is able to form
oligomeric complexes comprising at least three mono-
mers [30]. The 3-FRET signal was significantly reduced
by a combination of single point mutations of hydro-
phobic residues in TM4, findings that were also asso-
ciated with protein maturation and signaling function.
A similar conclusion has been reached with the dopa-
mine D2 receptor. Thus, cysteine cross-linking experi-
ments provided evidence for the involvement of TM1
and TM4 at the symmetrical interface of the dopamine
D2 receptor oligomer, and the cross-linking was differ-
entially affected by the presence of dopamine D2 ago-
nists or inverse agonists [31,32]. The combination of
bioluminescence/fluorescence complementation and
energy transfer approaches also suggested that the dopa-
mine D2 receptor form higher order oligomers in the
plasma membrane [33]. They propose a dopamine D2
receptor oligomer with a symmetric interface formed by
TM1 and the cytoplasmic helical domain (H8) in addi-
tion to the TM4 interface.
Serotonin 5-HT2A receptor and mGlu2 receptor form
a functional heterocomplex that has been implicated in
schizophrenia and psychosis [34,35]. The differences in
the capacity of the mGlu2 and mGlu3 receptors to exist
as a receptor complex with the 5-HT2A receptor
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tor TM domains responsible for GPCR heterocomplex
formation [34]. Study of a series of molecular chimeras
suggested that the segment containing TM4 and TM5
of the mGlu2 receptor was both necessary and sufficient
for complex formation with the 5-HT2A receptor. The
mGlu3 receptor chimera containing only this segment
from the mGlu2 receptor (mGlu3ΔTM4-5) was capable
of co-immunoprecipitating and maintaining close proxi-
mity with the 5-HT2A receptor as indicated by FRET. In
contrast, the chimera mGlu2 ΔTM4-5 did not show evi-
dence of complex formation with the 5-HT2A receptor.
Although all these findings support a contribution of
TM4 and TM1 to the formation of GPCR complexes,
the discrete structural components that affect this phe-
nomenon have not been unraveled.
Stability of GPCR oligomers
One question to be solved is the stability and lifetime of
t h eG P C Rc o m p l e x e si nt h ep l a s m am e m b r a n e .
Although GPCR oligomerization has been proposed to
be necessary for effective receptor maturation and sur-
face delivery [30,36], recent findings also suggest that
GPCRs exist in a dynamic equilibrium between mono-
meric and dimeric/oligomeric states. Thus, using a
fluorescence recovery after photobleaching (FRAP)
approach, Bunemann and collaborators demonstrated
that the b1-adrenergic receptor shows transients interac-
tions on a timescale of seconds [37]. However, for the
b2-adrenergic receptor, they found stable oligomers in
HEK293 cells and cardiac myocytes. Similar findings
using FRAP were obtained in studies examining the sta-
bility of dopamine D2 receptors, with which they
demonstrated a dynamic equilibrium between monomer
and homodimer/oligomer states of the dopamine D2
receptor [38].
The dynamic nature of dimer formation of muscarinic
M1 receptor has been recently detailed by using total
internal reflection fluorescence microscopy (TIRFM) in
living cells [39]. They visualized single muscarinic M1
receptors and found that they exist as monomers and
dimers, but not oligomers. They also found that ~30%
of the receptor molecules exist as a dimer at any given
time, and suggested that muscarinic M1 receptors do
not form constitutive dimers.
Signaling crosstalk
Several studies have demonstrated that GPCR hetero-
merization affects the pharmacological and cellular sig-
naling responses as compared to the different receptor
subtypes expressed alone. One well-studied example is
the receptor heterocomplex between the a2a-adrenergic
receptor and the μ-opioid receptor. a2a-Adrenergic
receptor and μ-opioid receptor have been repeatedly
involved in depression and opioid addiction [40-44].
Direct interaction between a2a-adrenergic and μ-opioid
receptors was demonstrated in tissue cultures and pri-
mary neurons [45]. Using this GPCR heterocomplex as
a model, Vilardaga and Lohse reported that a2a-adrener-
gic and μ-opioid receptors communicate one with each
other through the receptor complex [46]. They found
that morphine binding to the μ-opioid receptor induces
structural changes in the a2a-adrenergic receptor when
this is bound to norepinephrine. Previous findings
showed that whereas activation of either a2a-adrenergic
receptor or μ-opioid receptor increases phosphorilation
of ERK 1/2 in HEK293 cells and in primary spinal cord
neurons, activation of both receptors leads to a decrease
signal activation [45]. Using FRET microscopy, it was
found that the conformational changes induced in the
a2a-adrenergic receptor by morphine through the recep-
tor heterocomplex inhibit G protein coupling and the
ERK signaling pathway [46].
Another indication of GPCR heterocomplexes that
affect G protein coupling comes from studies on inter-
actions between 5-HT2A and mGlu2 receptors. The 5-
HT2A receptor and the mGlu2 receptor are usually
coupled to Gq/11 and Gi/o proteins, respectively. We
recently reported that hallucinogenic 5-HT2A receptor
agonists activate both Gq/11 and Gi/o proteins only when
the 5-HT2A receptor forms a receptor heterocomplex
with the mGlu2 receptor [34,47]. These findings have
been further supported in vivo in murine models. The
head-twitch is a behavioral response that is reliably eli-
cited by hallucinogens, and is absent in 5-HT2A-KO
mice [47]. We found that head-twitch response is abol-
ished in mGlu2-KO mice [48], which suggests that the
5-HT2A-mGlu2 receptor complex is necessary for the
behavioral responses induced by hallucinogenic 5-HT2A
receptor agonists (Figure 1).
Although these and other findings support the func-
tional and behavioral significance of GPCR heterocom-
plexes, many others demonstrate functional interactions
between GPCR subtypes that do not require formation
of GPCR complexes. It was reported that the GABAB
receptor potentiates the mGlu1 receptor-dependent sig-
naling, yet these two receptors do not associate with
each other [49]. Similarly, it has been shown that the
corticotropin-releasing factor 1 (CRF1) receptor modu-
lates G protein coupling and anxiety-like behaviors by
sensitizing 5-HT2A receptor-dependent signaling [50].
The mechanism of interaction between CRF1 and 5-
HT2A receptors is not direct, and requires scaffolding
proteins.
GPCR oligomers in native tissues
All the findings described above suggest the existence of
GPCR homo- and hetero-complexes in tissue cultures.
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stituted in lipid vesicles [51]. A fundamental question to
be addressed is the presence of GPCR complexes in
native tissue. Three recent publications using different
approaches support this hypothesis.
Reproduction in animals is dependent on the pulsatile
release of pituitary gonadotropic hormones: luitenizing
hormone (LH) and follicle-stimulating hormone (FSH).
In the testis, LH acts through LH receptors (LHR) on the
Leydig cells to regulate the production and secretion of
androgens. Biological actions of LH and FSH also include
maturation of testis and ovary [52]. Huhtaniemi and col-
leagues developed transgenic mice expressing mutant LH
receptors (LHR) in the absence of functional endogenous
receptor (i.e., in LHR-KO mice) [53]. They selected two
mutant LHRs that were not able to bind the ligand or to
modulate G protein coupling by agonist activation. The
first mutant LHR (Cys22Ala) is expressed on the cell sur-
face but is incapable of binding the LHR agonist hCG
[54]. The second mutant harbors a deletion (Val553 to
Ala689) that abolishes G protein coupling and cellular
signaling [55]. They confirmed in tissue cultures that the
first mutant (LHR
LH-) did not bind hCG and that the sec-
ond mutant (LHR
cAMP-) did not activate cAMP produc-
tion. Co-expression of LHR
LH- and LHR
cAMP- partially
rescued the cAMP response to hCG stimulation in
HEK293 cells [53]. Similar findings for agonist binding
and G protein coupling were also observed in the testes
of LHR
LH- and LHR
cAMP- mutant mice. They also found
that both transgenic mice showed a phenotype similar to
that of LHR-KO mice. This phenotype was rescued in
mice expressing both LHR
LH- and LHR
cAMP- receptors.
The testes were normally developed, and transgenic mice
expressing both LHR
LH- and LHR
cAMP- showed serum
hormone levels comparable to those seen in wild type
mice. The authors proposed intermolecular cooperation
in vivo as a potential mechanism to understand the phy-
siological relevance of these findings, and suggested
GPCR oligomerization as the biophysical basis of these
specific interactions.
Gq/11-dependent signaling  Gq/11- and Gi/o-dependent signaling
Head-twitch 
behavior:  No Yes 
LSD LSD 
5-HT2A  5-HT2A  mGlu2 
Figure 1 G protein-dependent signaling and behavioral responses that require a GPCR heterocomplex. Hallucinogenic drugs, such as
lysergic acid diethylamide (LSD), mescaline and psilocybin, all have in common a high affinity for the serotonin 5-HT2A receptor. Metabotropic
glutamate 2 receptor (mGlu2) and serotonin 5-HT2A receptor form a specific functional GPCR heterocomplex in mammalian brain and in tissue
culture preparations. mGlu2 transmembrane domains 4/5 mediate association with the 5-HT2A receptor. When 5-HT2A and mGlu2 are prevented
from forming a receptor heterocomplex, activation of 5-HT2A by LSD elicits signaling characteristic of Gq/11-protein subtypes. In contrast, LSD
acting at the 5-HT2A-mGlu2 receptor heterocomplex activates both Gq/11- and Gi/o-dependent signaling. Head-twitch behavior is reliably and
robustly elicited by hallucinogenic 5-HT2A agonists, and is absent in mGlu2 knockout mice.
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most commonly used approaches to validate in vivo the
significance of findings with GPCR heterocomplexes
obtained in tissue cultures. This assay suggests that
GPCRs might form heterocomplexes in native tissue.
Another possibility is that GPCRs form part of the same
protein complex, yet they interact indirectly through
scaffolding proteins, and are not in close proximity at
the plasma membrane. An essential tool to better define
the existence of close proximity is the development of
antibodies that only react when the two components of
the GPCR heterocomplex are co-expressed in the same
cell, and not when they are expressed alone. Using a
strategy of subtractive immunization, Devi and colla-
borators developed monoclonal antibodies to selectively
recognize the μ-δ opioid receptor heteromer, but not
either μ-opioid receptor or δ-opioid receptor, in the
central nervous system [56]. They detected μ-δ opioid
receptor heteromers in cortical membranes of wild type
mice, using μ-KO, δ-KO and μ-δ-KO mice as negative
controls. Chronic, but not acute, treatment with mor-
phine induced an increase in the expression of μ- and δ-
opioid receptors as a GPCR heterocomplex in brain
regions involved in drug addiction such as frontal cor-
tex, striatum and nucleus accumbens.
An interesting approach is the use of FRET with fluor-
escent ligands in native tissue. Albizu and Durroux opti-
mized the experimental conditions to perform
homogenous time-resolved FRET (HTRF) experiments
with the use of fluorescent ligands [57]. HTRF is based
on the derivation of GPCR ligands with a lanthanide
and a compatible fluorophore. The authors previously
generated fluorescent ligands for vasopressin and oxyto-
cin receptors [58], which are highly expressed in mam-
mary glands. Using fluorescent ligands, they obtained
FRET signal with native oxytocin receptors in rat mam-
mary glands [57]. Experiments revealing GPCR com-
plexes were performed both in membrane preparations
and in patches of native tissues. Taken together, these
findings suggest that GPCR are placed in close proxi-
mity in vivo in murine models.
Conclusions and Future Directions
The functional crosstalk observed in between the com-
ponents of GPCR heterocomplexes provides a unique
scenario for the rational design of new therapeutic
drugs. Examples of this include the 5-HT2A-mGlu2
receptor complex in schizophrenia [34], the μ-opioid-
a2a-adrenergic receptor complex in depression and
opioid addiction [45], the adenosine A2A-dopamine D2
receptor complex in Parkinson’s disease [59], and the
-δ-opioid receptor complex in analgesia and drug
abuse [23]. However, the majority of findings suggesting
the expression of these GPCRs as homo- and hetero-
oligomers have been reported using biochemical, bio-
physical and pharmacological approaches in tissue cul-
tures, and not in rodents. Only recently we have started
to make progress toward the ultimate goal of demon-
strating the physiological and behavioral relevance of
GPCR heterocomplexes in whole animal models. A
tempting approach to validate their significance is the
u s eo fk n o c k - i nm i c et h a te x p r e s st w oG P C R sa sf u n c -
tional homomers, but not as heteromers.
Unraveling the residues and domains that form part of
the GPCR complex interface might provide the basis for
the design of drugs that specifically affect the signaling
crosstalk between the components of the receptor com-
plex. Most of the findings obtained in tissue cultures
support the hypothesis that TM1 or TM4 and 5 form
the interfaces between GPCR monomers to form higher
order oligomers. However, crystal structures of the
CXCR4 chemokine receptor provide evidence for a sym-
metric dimer in which monomers interact only at the
extracellular side of TM5 and TM6 [60]. These findings
are different from previous observations, and make clear
the need for further research in the field. Interestingly,
the crystallization of rhodopsin revealed an antiparallel
dimer with respect to the plane of the membrane [61],
most probably due to the effects of solubilization proto-
cols on the physiologically relevant dimers.
Recent breakthroughs in the determination of the crys-
tal structures of GPCRs have provided indirect informa-
tion regarding G protein coupling. Comparison of the
inactive and active [63] structures of the b2-adrenergic
receptor suggests that the differences are mainly induced
at the cytoplasmic region of the receptor, with outward
displacement of TM5 and TM6 and inward movement of
TM7 and TM3 in the active relative to the inactive struc-
ture. In contrast, only small differences were observed
between the two protein structures in the agonist-binding
pocket. Heterotrimeric G proteins are composed of three
subunits: Ga,G b and g [64]. Recent findings based on
systematic cross-linking experiments have identified
many of the contact sites between muscarinic M3 recep-
tor and Gaq subunit [65]. In addition, Gb and g also play
a key role in determining receptor-G protein specificity
[66]. Since simultaneous interaction of the receptor with
both Ga and Gbg subunits is required for G protein acti-
vation, and based on the size of the intracellular region of
the receptor exposed to the cytoplasm, it is tempting to
speculate that a single receptor might show limited cou-
pling to the heterotrimeric G protein. Although this
hypothesis is supported by the development of a func-
tional complementation assay that points to two recep-
tors and a single G protein as the minimal signaling unit
of the dopamine D2 receptor [67], it has also been shown
that rhodopsin [68] and the b2-adrenergic receptor [69]
signal efficiently to G proteins when reconstituted into
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dies will be needed to better understand the complexity
of receptor-G protein coupling [70,71], and the role of
GPCR homo-and hetero-complexes in receptor signaling.
Despite the advances in our knowledge of structure and
function of GPCRs, much more needs to be learned
about the pharmacology, neuroanatomy and signaling of
GPCR oligomers both in vitro and in mouse models
before developing new therapeutic drugs that affect their
function.
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